Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

NLR and LTR Nigeria make a new start to stop leprosy transmission in Nigeria

This image opens in the lightbox

News provided by

NLR | until No Leprosy Remains

14 Jul, 2021, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

AMSTERDAM, July 14, 2021 /PRNewswire/ -- On Tuesday July 13th LTR Nigeria organized the kickoff event of Ready4PEP, an innovative 4-year implementation project, at the District Head's Palace in Misau local government area, Bauchi State. The launch means the first hand out of a new preventive medicine for contacts of leprosy patients. In the presence of national media, local authorities, health workers and persons affected by leprosy, the first close contacts of leprosy patients received the antibiotic rifampicin. This medicine is proven to interrupt the spread and devastating effects of leprosy. During the event, two men, three women and three children received the preventive treatment. The project is coordinated by NLR, until no Leprosy Remains (NLR) and LTR Nigeria in close collaboration with national health authorities.

Continue Reading
This image opens in the lightbox
Child receiving SDR-PEP, a preventive treatment for leprosy, in Nigeria

Research shows that the combination of contact screening and the provision of a single-dose of rifampicin as post-exposure prophylaxis (SDR-PEP) is effective and feasible. The World Health Organization (WHO) recommends national programmes to initiate SDR-PEP. According to the WHO 2019 leprosy update, Nigeria had 2,424 newly detected leprosy patients, thereby accounting for about ten percent of the total new leprosy patients in Africa. Nigeria is one of the first countries to implement SDR-PEP on a larger scale. A total of 21,000 contacts are expected to receive SDR-PEP.

Implementing SDR-PEP in Nigeria

The approach to successfully implement SDR-PEP considers four crucial elements: active case finding, geological mapping, capacity building of health workers and distribution of medication. Since the start of 2020, NLR and LTR Nigeria in close collaboration with the national tuberculosis and leprosy control programme, the German Leprosy and Tuberculosis Relief Association (GLRA) and the Leprosy Mission Nigeria (TLMN) took all preparatory steps to start the final step, distributing SDR-PEP to the contacts of confirmed leprosy patients.

Health workers visited each contact and screened them for signs and symptoms of leprosy. Contacts that did not display signs and symptoms of the disease, and meet the eligibility criteria for SDR-PEP administration, will now start to receive a single dose of rifampicin. The contacts of all new leprosy patients in the projects intervention areas will also be screened for leprosy, continuing the cycle.

Bauchi State, where the event takes place, is one of the six Ready4PEP implementation states and among the top 15 leprosy high burden states in Nigeria. The intervention areas are located in the North-East/North-West (LTR Nigeria), South-East/South-South (GLRA) and North-West/North-Central (TLM Nigeria) of the country. This results in a more diversified pattern of areas with a very different sociocultural and socioeconomic context and different approaches used by the project partners. "Now there is hope. Leprosy can be debilitating and disfiguring, but leprosy is curable and now even preventable. This project shows that this intervention is for the community and we are all stakeholders," says Dr. Suleiman Abdullahi, Medical Adviser LTR Nigeria.

Ready4PEP project

In NLR's Ready4PEP project a preventive treatment to stop leprosy transmission, SDR-PEP, is implemented in Mozambique and Nigeria. The goal is to interrupt the spread and harmful effects of leprosy through well thought-out interventions targeting a range of stakeholders. The governments of both countries have shown enthusiasm and willingness to work together with the partners in this project to introduce SDR-PEP into their leprosy control programmes and improve care for persons affected. The Nigerian National Programme on TB, Buruli ulcer and Leprosy (NPTBL) is committed towards the project and staff was present at the launch event. The distribution of medication will soon start in Mozambique as well. Both countries account for over twenty percent of the total new leprosy patients in Africa.

About NLR | until No Leprosy Remains

NLR is an international NGO that has been one of the major change-makers in the fight against leprosy in the past 50 years. NLR takes focuses on research and driving evidence-based innovation to achieve zero transmission, zero disability and zero discrimination due to leprosy. NLR has offices in some of the most leprosy-endemic countries: India, Brazil, Indonesia, Mozambique and Nepal and an international office in the Netherlands. A worldwide total of 200 staff work together to achieve zero leprosy. We continue our efforts until No Leprosy Remains. Find out more: www.nlrinternational.org/ready4pep

About LTR Nigeria

Leprosy and Tuberculosis Relief Initiative Nigeria (LTR) is a non-profit NGO. The organization is passionate and committed to Leprosy and Tuberculosis control in Nigeria. From 1978 to 2017, LTR was a regional office of NLR. The entity LTR was incorporated in 2018 and still partners with NLR in Nigeria, to achieve a leprosy-free world. https://ltrnigeria.org/ 

Available for interviews

  • Karin van Knippenberg – Project Coordinator Ready4PEP at NLR
  • Dr. Tahir Dahiru – Executive Director LTR Nigeria
  • Dr. Suleiman Abdullahi, Medical Adviser LTR Nigeria


Photo: https://mma.prnewswire.com/media/1573120/SDR_PEP.jpg

Logo: https://mma.prnewswire.com/media/1305576/NLR_logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.